Myriad Genetics, Inc. (MYGN) Tops Q2 EPS by 2c, Raises FY12 Outlook
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $5.22 +12.74%
EPS Growth %: -220.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
YRD, NNOX, BB, More
EPS Growth %: -220.0%
Financial Fact:
Molecular diagnostic testing: 165.1M
Today's EPS Names:
YRD, NNOX, BB, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q2 EPS of $0.33, $0.02 better than the analyst estimate of $0.31. Revenue for the quarter came in at $122.8 million versus the consensus estimate of $115.28 million.
Myriad Genetics, Inc. sees FY2012 EPS of $1.24-$1.28, versus prior guidance of $1.20-$1.25 and the consensus of $1.24. Myriad Genetics, Inc. sees FY2012 revenue of $465-$475 million, versus prior guidance of $445-$465 million and the consensus of $461.45 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Myriad Genetics, Inc. sees FY2012 EPS of $1.24-$1.28, versus prior guidance of $1.20-$1.25 and the consensus of $1.24. Myriad Genetics, Inc. sees FY2012 revenue of $465-$475 million, versus prior guidance of $445-$465 million and the consensus of $461.45 million.
For earnings history and earnings-related data on Myriad Genetics, Inc. (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
- JPMorgan Starts Accton Technology Corp. (2345:TT) at Overweight
- Micron Technology (MU) PT Raised to $1,100 at Goldman Sachs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
